Tenderwize
Retour à la recherche

Inhibiteur de tyrosine kinase à base de crizotinib

Fakultní nemocnice Ostrava·Ostrava, Czech Republic·CZK 8M | EUR 326.6k·Deadline Dec 15, 2026 · 25 days left·Open·Supplies
Structured notice only
Titre original de l'avis

Czechia – Antineoplastic agents – Cytostatikum, inhibitor tyrozinkináz s účinnou látkou Crizotinibum

61/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

61 / 100

Complexité

58 / 100

Facteurs de risque

Important procurement documents and annexes are referenced but their contents were not provided, so material requiremen...

The available notice does not state quantities, expected consumption, order frequency, delivery lead times, or exact de...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Informations clés

Pouvoir adjudicateur
Fakultní nemocnice Ostrava
Pays
République tchèque
CPV
33652100 - Antineoplastic agents
Date limite
Dec 15, 2026
Valeur estimée
CZK 8M (approx. EUR 326.6k)

Aperçu

Moderate opportunity

Faits clés

  • CZK 8M estimated value
  • Supplies contract
  • 1 lot
  • Duration 48 MONTH
  • Recurring and repeated deliveries of crizotinib medicinal products.
  • Supply of hard capsules containing 200 mg and 250 mg of crizotinib per capsule.
Afficher le résumé complet

Open procedure for recurring and repeated supplies of crizotinib hard capsules in 200 mg and 250 mg strengths over 48 months. The lead contracting buyer is Fakultní nemocnice Ostrava, with Fakultní nemocnice Hradec Králové listed as a non-lead participating buyer. Submission is electronic through the stated e-procurement profile. The notice provides a clear price-only award basis, but procurement documents and detailed eligibility, quantities, delivery terms, and contractual conditions were not analyzed.

Risques

Important procurement documents and annexes are referenced but their contents were not provided, so material requiremen...

The available notice does not state quantities, expected consumption, order frequency, delivery lead times, or exact de...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • The procedure is open.

Administrative

  • Electronic submission is required.
  • The submission channel is the Fakultní nemocnice Ostrava e-procurement profile.

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

Lowest price, weighted 100%. — 100%

Acheteur

Localisation

Ostrava, CZE

Site web

www.fno.cz/

Profil acheteur

Ouvrir le profil

Identifiant

00843989

Activité

Health

Lots (1)

LOT-0001

Crizotinib antineoplastic medicinal product

Recurring and repeated supplies of crizotinib medicinal product, a tyrosine kinase inhibitor, in 200 mg and 250 mg strengths in hard capsules. The lot has a 48-month duration and is performed in Czechia, with structured data identifying subdivision CZ080.

SuppliesEU fundedElectronic submission

EUR 326.6k

Valeur estimée

Localisation

CZ080, Czech Republic

Durée

48 MONTH

Catégorie

Antineoplastic agents

Critères d'attribution

Price

Date limite

Deadline Dec 15, 2026

Détails de la procédure

Date de publication
12 Nov 2026
Langues
Czech

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
790827-2026

Documents (1)

Appels d'offres similaires

Cookies & Privacy

With your consent, we use Google Analytics, Microsoft Clarity (session recordings) and Google Ads cookies to understand how Tenderwize is used and to measure our advertising. You can change your choice at any time via “Cookie Settings” in the footer. Cookie Policy · Privacy Policy